![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
HOT stock here trading significantly below cash balance , FDA acceptance expected within days with potential FDA decision in Q3 this year . Stock has very strong insider and institutional ownership .This stock is a potential 10 bagger potential play because of its super low valuation . Clearside BioMedical (CLSD) Market Cap $39 Million Cash $65 Million Price 1.23 Shares Out 32 million Clearside Biomedical submits NDA for XIPERE in macular edema associated with uveitis biotuesdays.com Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide. If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024. New Presentation ir.clearsidebio.com Product Pipeline clearsidebio.com Largest shareholders : Wellington Management Co. LLP 4 397 523 Hatteras Venture Partners 3 466 394 Bradford T. Whitmore, MBA 3 200 000 BlackRock Fund Advisors 1 764 105 The Vanguard Group, Inc. 1 198 301 Sphera Funds Management Ltd. 1 154 690 Rock Springs Capital Management LP 975 000 Millennium Management LLC 899 428 AWM Investment Co., Inc. 875 126 Sofinnova Ventures, Inc. 606 914 | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |